First Time Loading...

Immunovant Inc
NASDAQ:IMVT

Watchlist Manager
Immunovant Inc Logo
Immunovant Inc
NASDAQ:IMVT
Watchlist
Price: 32.52 USD 3.47% Market Closed
Updated: Mar 28, 2024

Intrinsic Value

Immunovant, Inc. is a clinical-stage biopharmaceutical company. [ Read More ]

There is not enough data to reliably calculate the intrinsic value of IMVT.

Key Points:
IMVT Intrinsic Value
Base Case
Not Available
Base Case Scenario

Fundamental Analysis

How can I assist you today?

Provide an overview
of Immunovant Inc's business.

What risks and challenges
does Immunovant Inc face in the near future?

Summarize the latest earnings report
of Immunovant Inc.

Provide P/E
for Immunovant Inc and its competitors.

Financials

Balance Sheet Decomposition
Immunovant Inc

Current Assets 710.8m
Cash & Short-Term Investments 690.9m
Receivables 1m
Other Current Assets 18.8m
Non-Current Assets 670k
PP&E 670k
Current Liabilities 32.1m
Accounts Payable 3.9m
Accrued Liabilities 28.2m
Efficiency

Earnings Waterfall
Immunovant Inc

Revenue
0 USD
Operating Expenses
-253.6m USD
Operating Income
-253.6m USD
Other Expenses
10.1m USD
Net Income
-243.4m USD

Free Cash Flow Analysis
Immunovant Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

IMVT Profitability Score
Profitability Due Diligence

Immunovant Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.

29/100
Profitability
Score

Immunovant Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.

IMVT Solvency Score
Solvency Due Diligence

Immunovant Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Immunovant Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

IMVT Price Targets Summary
Immunovant Inc

Wall Street analysts forecast IMVT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for IMVT is 51.73 USD with a low forecast of 40.4 USD and a high forecast of 59.85 USD.

Lowest
Price Target
40.4 USD
24% Upside
Average
Price Target
51.73 USD
59% Upside
Highest
Price Target
59.85 USD
84% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

IMVT Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

IMVT Price
Immunovant Inc

1M 1M
-14%
6M 6M
-18%
1Y 1Y
+110%
3Y 3Y
+113%
5Y 5Y
+227%
10Y 10Y
+227%
Annual Price Range
32.52
52w Low
14.2
52w High
44.19
Price Metrics
Average Annual Return 70.22%
Standard Deviation of Annual Returns 114.64%
Max Drawdown -94%
Shares Statistics
Market Capitalization 4.7B USD
Shares Outstanding 145 292 992
Percentage of Shares Shorted 12.42%

IMVT Return Decomposition
Main factors of price return

What is price return decomposition?

IMVT News

Last Important Events
Immunovant Inc

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Immunovant Inc

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Immunovant Inc Logo
Immunovant Inc

Country

United States of America

Industry

Biotechnology

Market Cap

4.7B USD

Dividend Yield

0%

Description

Immunovant, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 68 full-time employees. The company went IPO on 2019-05-14. The firm is focused on developing treatments for patients with autoimmune diseases. The firm is developing IMVT-1401, a human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies. IMVT-1401 is being developed to target the neonatal Fc receptor (FcRn). The company is also developing IMVT-1401 as a fixed-dose subcutaneous injection and focused initial development on the treatment of myasthenia gravis (MG), warm autoimmune hemolytic anemia (WAIHA), and thyroid eye disease (TED).

Contact

NEW YORK
New York City
320 West 37Th Street
+19175803099.0
https://immunovant.com/

IPO

2019-05-14

Employees

68

Officers

Executive Chairperson of the Board
Dr. Frank M. Torti M.B.A., M.D.
CEO & Director
Dr. Peter Salzmann M.B.A., M.D.
Chief Financial Officer
Ms. Eva Renee Barnett M.B.A.
Chief Medical Officer
Dr. William L. Macias M.D., Ph.D.
Chief Technology Officer
Dr. Jay S. Stout Ph.D.
Vice President of Investor Relations
Dr. Chau Cheng M.B.A., Ph.D.
Show More
Chief Legal Officer & Corporate Secretary
Mr. Mark S. Levine
Vice President of Marketing
Ms. Lauren Schrier M.B.A.
Vice President of Human Resources
Ms. Christine Blodgett
Chief Development Officer
Dr. Julia G. Butchko Ph.D.
Show Less

See Also

Discover More